APOE and early-onset autosomal dominant Alzheimer disease: This suggests that if the Szekely et al. finding is due to NSAID-ApoE4 interactions, and not hidden nuisance variables present in the analysis, then this therapeutic effect may only be useful for the prophylactic treatment to prevent Alzheimer disease in ApoE4 individuals and not effective in altering the progression of the disease.